|

YL202 Clinical Trials

3 actively recruiting trials

▲ +1 trial since June 2026

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • MediLink Therapeutics (Suzhou) Co., Ltd.3

Indications

  • Cancer3
  • Lung Cancer2
  • Non Small Cell Lung Cancer2
  • Locally Advanced or Metastatic Solid Tumors1
  • Locally Advanced or Metastatic Breast Cancer1

Other3 trials

A Study of YL202 in Patients With Advanced Solid Tumors
Phase 2
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Phase 3
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.